{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T03:54:14Z","timestamp":1791950054185,"version":"4.3.4"},"reference-count":142,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,8,2]],"date-time":"2018-08-02T00:00:00Z","timestamp":1533168000000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"NIH","award":["R01 CA211044-01"],"award-info":[{"award-number":["R01 CA211044-01"]}]},{"DOI":"10.13039\/100004917","name":"Cancer Prevention Research Institute of Texas","doi-asserted-by":"crossref","award":["RSG-15-218-01-LIB"],"award-info":[{"award-number":["RSG-15-218-01-LIB"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1016\/j.ymthe.2017.06.012","type":"journal-article","created":{"date-parts":[[2017,6,28]],"date-time":"2017-06-28T23:46:01Z","timestamp":1498693561000},"page":"1769-1781","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":409,"title":["Engineering Natural Killer Cells for Cancer Immunotherapy"],"prefix":"10.1016","volume":"25","author":[{"given":"Katayoun","family":"Rezvani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rayne","family":"Rouce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enli","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Shpall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2017.06.012_bib1","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T\u00a0cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2017.06.012_bib2","doi-asserted-by":"crossref","first-page":"224ra25","DOI":"10.1126\/scitranslmed.3008226","article-title":"Efficacy and toxicity management of 19-28z CAR T\u00a0cell therapy in B cell acute lymphoblastic leukemia","volume":"6","author":"Davila","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2017.06.012_bib3","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","article-title":"T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial","volume":"385","author":"Lee","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.ymthe.2017.06.012_bib4","doi-asserted-by":"crossref","first-page":"280ps7","DOI":"10.1126\/scitranslmed.aaa3643","article-title":"Adoptive cellular therapy: a race to the finish line","volume":"7","author":"June","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2017.06.012_bib5","doi-asserted-by":"crossref","first-page":"3392","DOI":"10.1172\/JCI80010","article-title":"CAR therapy: the CD19 paradigm","volume":"125","author":"Sadelain","year":"2015","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.ymthe.2017.06.012_bib6","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.smim.2014.02.004","article-title":"Natural killer cells in the treatment of high-risk leukemia","volume":"26","author":"Locatelli","year":"2014","journal-title":"Semin. Immunol."},{"key":"10.1016\/j.ymthe.2017.06.012_bib7","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.blre.2005.10.001","article-title":"Human natural killer cell development and biology","volume":"20","author":"Farag","year":"2006","journal-title":"Blood Rev."},{"key":"10.1016\/j.ymthe.2017.06.012_bib8","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1182\/blood-2010-08-264085","article-title":"Killer Ig-like receptor-mediated control of natural killer cell alloreactivity in haploidentical hematopoietic stem cell transplantation","volume":"117","author":"Moretta","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2017.06.012_bib9","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1038\/bmt.2009.304","article-title":"Generation of donor natural killer cells from CD34(+) progenitor cells and subsequent infusion after HLA-mismatched allogeneic hematopoietic cell transplantation: a feasibility study","volume":"45","author":"Yoon","year":"2010","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.ymthe.2017.06.012_bib10","doi-asserted-by":"crossref","first-page":"3051","DOI":"10.1182\/blood-2004-07-2974","article-title":"Successful adoptive transfer and in\u00a0vivo expansion of human haploidentical NK cells in patients with cancer","volume":"105","author":"Miller","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2017.06.012_bib11","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1200\/JCO.2009.24.4590","article-title":"NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia","volume":"28","author":"Rubnitz","year":"2010","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.ymthe.2017.06.012_bib12","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1158\/2159-8290.CD-15-1020","article-title":"Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy","volume":"5","author":"Sotillo","year":"2015","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ymthe.2017.06.012_bib13","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1038\/nature03847","article-title":"Licensing of natural killer cells by host major histocompatibility complex class I molecules","volume":"436","author":"Kim","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2017.06.012_bib14","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/j.jcyt.2014.03.009","article-title":"Opportunities and limitations of NK cells as adoptive therapy for malignant disease","volume":"16","author":"Davies","year":"2014","journal-title":"Cytotherapy"},{"key":"10.1016\/j.ymthe.2017.06.012_bib15","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.bbmt.2016.11.018","article-title":"Cytokine-induced memory-like differentiation enhances unlicensed natural killer cell antileukemia and Fc\u03b3RIIIa-triggered responses","volume":"23","author":"Wagner","year":"2016","journal-title":"Biol. Blood Marrow Transplant"},{"key":"10.1016\/j.ymthe.2017.06.012_bib16","doi-asserted-by":"crossref","first-page":"3146","DOI":"10.1182\/blood.V97.10.3146","article-title":"Human natural killer cells: a unique innate immunoregulatory role for the CD56(bright) subset","volume":"97","author":"Cooper","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2017.06.012_bib17","doi-asserted-by":"crossref","first-page":"6477","DOI":"10.4049\/jimmunol.166.11.6477","article-title":"Unique subpopulations of CD56+ NK and NK-T peripheral blood lymphocytes identified by chemokine receptor expression repertoire","volume":"166","author":"Campbell","year":"2001","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.ymthe.2017.06.012_bib18","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1073\/pnas.1012356108","article-title":"Revisiting human natural killer cell subset function revealed cytolytic CD56(dim)CD16+ NK cells as rapid producers of abundant IFN-gamma on activation","volume":"108","author":"De Maria","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2017.06.012_bib19","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1126\/science.1070538","article-title":"Immunology. A perfect mismatch","volume":"295","author":"K\u00e4rre","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2017.06.012_bib20","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.jaci.2013.07.006","article-title":"Natural killer cell biology: an update and future directions","volume":"132","author":"Campbell","year":"2013","journal-title":"J.\u00a0Allergy Clin. Immunol."},{"key":"10.1016\/j.ymthe.2017.06.012_bib21","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1182\/blood-2007-09-077438","article-title":"Human natural killer cells","volume":"112","author":"Caligiuri","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2017.06.012_bib22","doi-asserted-by":"crossref","first-page":"4248","DOI":"10.1182\/blood.V92.11.4248","article-title":"Role of spontaneous and interleukin-2-induced natural killer cell activity in the cytotoxicity and rejection of Fas1 and Fas- tumor cells","volume":"92","author":"Bradley","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2017.06.012_bib23","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.4049\/jimmunol.167.4.2068","article-title":"A central role for death receptor-mediated apoptosis in the rejection of tumors by NK cells","volume":"167","author":"Screpanti","year":"2001","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.ymthe.2017.06.012_bib24","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.4049\/jimmunol.163.4.1906","article-title":"Expression and function of TNF-related apoptosis-inducing ligand on murine activated NK cells","volume":"163","author":"Kayagaki","year":"1999","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.ymthe.2017.06.012_bib25","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1084\/jem.20100570","article-title":"Mature natural killer cells reset their responsiveness when exposed to an altered MHC environment","volume":"207","author":"Joncker","year":"2010","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.ymthe.2017.06.012_bib26","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/0145-2126(87)90158-5","article-title":"Inhibition of clonogenic growth of fresh leukemia cells by unstimulated and IL-2 stimulated NK cells of normal donors","volume":"11","author":"Lotzov\u00e1","year":"1987","journal-title":"Leuk. Res."},{"key":"10.1016\/j.ymthe.2017.06.012_bib27","doi-asserted-by":"crossref","first-page":"836","DOI":"10.3324\/haematol.2013.087536","article-title":"Leukemia-induced phenotypic and functional defects in natural killer cells predict failure to achieve remission in acute myeloid leukemia","volume":"99","author":"Stringaris","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.ymthe.2017.06.012_bib28","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1182\/blood-2005-08-027979","article-title":"Deficient expression of NCR in NK cells from acute myeloid leukemia: evolution during leukemia treatment and impact of leukemia cells in NCRdull phenotype induction","volume":"109","author":"Fauriat","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2017.06.012_bib29","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1016\/j.jcyt.2014.03.008","article-title":"Upregulation of NKG2D ligands in acute lymphoblastic leukemia and non-Hodgkin lymphoma cells by romidepsin and enhanced in\u00a0vitro and in\u00a0vivo natural killer cell cytotoxicity","volume":"16","author":"Satwani","year":"2014","journal-title":"Cytotherapy"},{"key":"10.1016\/j.ymthe.2017.06.012_bib30","doi-asserted-by":"crossref","first-page":"79187","DOI":"10.18632\/oncotarget.13007","article-title":"The anti-tumor role of NK cells in\u00a0vivo pre-activated and restimulated by interleukins in acute lymphoblastic leukemia","volume":"7","author":"Jin","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.ymthe.2017.06.012_bib31","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1038\/leu.2015.327","article-title":"The TGF-\u03b2\/SMAD pathway is an important mechanism for NK cell immune evasion in childhood B-acute lymphoblastic leukemia","volume":"30","author":"Rouce","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.ymthe.2017.06.012_bib32","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/j.1365-2141.2007.06631.x","article-title":"Intensity of HLA class I expression and KIR-mismatch determine NK-cell mediated lysis of leukaemic blasts from children with acute lymphatic leukaemia","volume":"138","author":"Pfeiffer","year":"2007","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.ymthe.2017.06.012_bib33","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1615\/CritRevOncog.2014011091","article-title":"NK cells in therapy of cancer","volume":"19","author":"Bachanova","year":"2014","journal-title":"Crit. Rev. Oncog."},{"key":"10.1016\/j.ymthe.2017.06.012_bib34","doi-asserted-by":"crossref","first-page":"e76781","DOI":"10.1371\/journal.pone.0076781","article-title":"Antigen presenting cell-mediated expansion of human umbilical cord blood yields log-scale expansion of natural killer cells with anti-myeloma activity","volume":"8","author":"Shah","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ymthe.2017.06.012_bib35","doi-asserted-by":"crossref","first-page":"8444","DOI":"10.1158\/0008-5472.CAN-06-4230","article-title":"Requirement for DNAM-1, NKG2D, and NKp46 in the natural killer cell-mediated killing of myeloma cells","volume":"67","author":"El-Sherbiny","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.ymthe.2017.06.012_bib36","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.3324\/haematol.2011.054254","article-title":"Natural killer cell lines preferentially kill clonogenic multiple myeloma cells and decrease myeloma engraftment in a bioluminescent xenograft mouse model","volume":"97","author":"Swift","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/j.ymthe.2017.06.012_bib37","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1182\/blood.V98.1.210","article-title":"Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma","volume":"98","author":"Davies","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2017.06.012_bib38","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1158\/1078-0432.CCR-12-1243","article-title":"Growth and activation of natural killer cells ex\u00a0vivo from children with neuroblastoma for adoptive cell therapy","volume":"19","author":"Liu","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2017.06.012_bib39","doi-asserted-by":"crossref","first-page":"3499","DOI":"10.1158\/0008-5472.CAN-13-0371","article-title":"Immune infiltrates are prognostic factors in localized gastrointestinal stromal tumors","volume":"73","author":"Rusakiewicz","year":"2013","journal-title":"Cancer Res."},{"key":"10.1016\/j.ymthe.2017.06.012_bib40","doi-asserted-by":"crossref","first-page":"3609","DOI":"10.1172\/JCI45816","article-title":"Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity","volume":"121","author":"Mamessier","year":"2011","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.ymthe.2017.06.012_bib41","doi-asserted-by":"crossref","first-page":"202","DOI":"10.3389\/fimmu.2015.00202","article-title":"Therapeutic potential\u00a0and challenges of natural killer cells in treatment of solid tumors","volume":"6","author":"Gras Navarro","year":"2015","journal-title":"Front. Immunol"},{"key":"10.1016\/j.ymthe.2017.06.012_bib42","doi-asserted-by":"crossref","first-page":"e1250050","DOI":"10.1080\/2162402X.2016.1250050","article-title":"Targeting Ewing sarcoma with activated and GD2-specific chimeric antigen receptor-engineered human NK cells induces upregulation of immune-inhibitory HLA-G","volume":"6","author":"Kailayangiri","year":"2016","journal-title":"OncoImmunology"},{"key":"10.1016\/j.ymthe.2017.06.012_bib43","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1111\/j.1537-2995.2012.03724.x","article-title":"Natural killer cells: a review of manufacturing and clinical utility","volume":"53","author":"Koepsell","year":"2013","journal-title":"Transfusion"},{"key":"10.1016\/j.ymthe.2017.06.012_bib44","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.bbmt.2014.01.006","article-title":"Pre-activation with IL-12, IL-15, and IL-18 induces CD25 and a functional high affinity IL-2 receptor on human cytokine-induced memory-like NK cells","volume":"20","author":"Leong","year":"2014","journal-title":"Biol. Blood Marrow Transplant"},{"key":"10.1016\/j.ymthe.2017.06.012_bib45","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1016\/j.bbmt.2014.05.004","article-title":"Expansion and homing of adoptively transferred human natural killer cells in immunodeficient mice varies with product preparation and in\u00a0vivo cytokine administration: implications for clinical therapy","volume":"20","author":"Miller","year":"2014","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.ymthe.2017.06.012_bib46","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1080\/14653240902807034","article-title":"Berg. Clinical-grade ex\u00a0vivo-expanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells","volume":"11","author":"Berg","year":"2009","journal-title":"Cytotherapy"},{"key":"10.1016\/j.ymthe.2017.06.012_bib47","doi-asserted-by":"crossref","first-page":"578","DOI":"10.3389\/fimmu.2015.00578","article-title":"The application of natural killer cell immunotherapy for the treatment of cancer","volume":"6","author":"Rezvani","year":"2015","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2017.06.012_bib48","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1084\/jem.20120944","article-title":"Sustained effector function of IL-12\/15\/18-preactivated NK cells against established tumors","volume":"209","author":"Ni","year":"2012","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.ymthe.2017.06.012_bib49","doi-asserted-by":"crossref","first-page":"3241","DOI":"10.1182\/blood-2014-04-569061","article-title":"Antibody Fc engineering improves frequency and promotes kinetic boosting of serial killing mediated by NK cells","volume":"124","author":"Romain","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2017.06.012_bib50","doi-asserted-by":"crossref","first-page":"5075","DOI":"10.1158\/1078-0432.CCR-14-0580","article-title":"Anti-CCR4 monoclonal antibody mogamulizumab for the treatment of EBV-associated T- and NK-cell lymphoproliferative diseases","volume":"20","author":"Kanazawa","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2017.06.012_bib51","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1182\/blood-2007-11-122465","article-title":"Fc-dependent expression of CD137 on human NK cells: insights into \u201cagonistic\u201d effects of anti-CD137 monoclonal antibodies","volume":"112","author":"Lin","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2017.06.012_bib52","doi-asserted-by":"crossref","first-page":"6387","DOI":"10.1182\/blood-2011-06-360255","article-title":"IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect","volume":"118","author":"Benson","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2017.06.012_bib53","doi-asserted-by":"crossref","first-page":"5618","DOI":"10.4049\/jimmunol.1400288","article-title":"KIR\/HLA interactions negatively affect rituximab- but not GA101 (obinutuzumab)-induced antibody-dependent cellular cytotoxicity","volume":"192","author":"Terszowski","year":"2014","journal-title":"J.\u00a0Immunol"},{"key":"10.1016\/j.ymthe.2017.06.012_bib54","doi-asserted-by":"crossref","first-page":"3273","DOI":"10.1182\/blood-2011-01-329508","article-title":"Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients","volume":"118","author":"Curti","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2017.06.012_bib55","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1002\/pbc.25555","article-title":"Natural killer cell therapy in children with relapsed leukemia","volume":"62","author":"Rubnitz","year":"2015","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.ymthe.2017.06.012_bib56","doi-asserted-by":"crossref","first-page":"6094","DOI":"10.1182\/blood-2008-06-165225","article-title":"Human embryonic stem cells differentiate into a homogeneous population of natural killer cells with potent in\u00a0vivo antitumor activity","volume":"113","author":"Woll","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2017.06.012_bib57","doi-asserted-by":"crossref","first-page":"95","DOI":"10.3389\/fimmu.2014.00095","article-title":"Improving the outcome of leukemia by natural killer cell-based immunotherapeutic strategies","volume":"5","author":"Chouaib","year":"2014","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2017.06.012_bib58","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jcyt.2014.12.001","article-title":"Cord blood: a promising source of allogeneic natural killer cells for immunotherapy","volume":"17","author":"Shaim","year":"2015","journal-title":"Cytotherapy"},{"key":"10.1016\/j.ymthe.2017.06.012_bib59","doi-asserted-by":"crossref","first-page":"e30264","DOI":"10.1371\/journal.pone.0030264","article-title":"Membrane-bound IL-21 promotes sustained ex\u00a0vivo proliferation of human natural killer cells","volume":"7","author":"Denman","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ymthe.2017.06.012_bib60","first-page":"68","article-title":"A cytotoxic NK-cell line (NK-92) for ex\u00a0vivo purging of leukemia from blood","volume":"2","author":"Klingemann","year":"1996","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.ymthe.2017.06.012_bib61","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1016\/j.jcyt.2013.06.017","article-title":"Treatment of patients with advanced cancer with the natural killer cell line NK-92","volume":"15","author":"Tonn","year":"2013","journal-title":"Cytotherapy"},{"key":"10.1016\/j.ymthe.2017.06.012_bib62","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1126\/science.1068440","article-title":"Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants","volume":"295","author":"Ruggeri","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2017.06.012_bib63","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2009-05-222190","article-title":"NK cells mediate reduction of GVHD by inhibiting activated, alloreactive T\u00a0cells while retaining GVT effects","volume":"115","author":"Olson","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2017.06.012_bib64","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1038\/sj.leu.2403524","article-title":"Purified donor NK-lymphocyte infusion to consolidate engraftment after haploidentical stem cell transplantation","volume":"18","author":"Passweg","year":"2004","journal-title":"Leukemia"},{"key":"10.1016\/j.ymthe.2017.06.012_bib65","doi-asserted-by":"crossref","first-page":"e1115178","DOI":"10.1080\/2162402X.2015.1115178","article-title":"Advances in clinical NK cell studies: donor selection, manufacturing and quality control","volume":"5","author":"Koehl","year":"2015","journal-title":"OncoImmunology"},{"key":"10.1016\/j.ymthe.2017.06.012_bib66","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1073\/pnas.90.2.720","article-title":"Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors","volume":"90","author":"Eshhar","year":"1993","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2017.06.012_bib67","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1111\/bjh.14470","article-title":"Recent advances in T-cell immunotherapy for haematological malignancies","volume":"176","author":"Rouce","year":"2017","journal-title":"Br. J. Haematol"},{"key":"10.1016\/j.ymthe.2017.06.012_bib68","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.coi.2016.06.004","article-title":"Chimeric antigen receptors: driving immunology towards synthetic biology","volume":"41","author":"Sadelain","year":"2016","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.ymthe.2017.06.012_bib69","doi-asserted-by":"crossref","first-page":"3363","DOI":"10.1172\/JCI86721","article-title":"Phase I trials using sleeping beauty to generate CD19-specific CAR T\u00a0cells","volume":"126","author":"Kebriaei","year":"2016","journal-title":"J.\u00a0Clin. Invest"},{"key":"10.1016\/j.ymthe.2017.06.012_bib70","doi-asserted-by":"crossref","first-page":"2965","DOI":"10.1182\/blood-2013-06-506741","article-title":"Infusion of donor-derived CD19-redirected virus-specific T\u00a0cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study","volume":"122","author":"Cruz","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2017.06.012_bib71","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1038\/nm.4258","article-title":"Donor CD19 CAR T\u00a0cells exert potent graft-versus-lymphoma activity with diminished graft-versus-host activity","volume":"23","author":"Ghosh","year":"2017","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2017.06.012_bib72","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1158\/1078-0432.CCR-16-1300","article-title":"Multiplex genome editing to generate universal CAR T\u00a0cells resistant to PD1 inhibition","volume":"23","author":"Ren","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2017.06.012_bib73","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1200\/JCO.2015.64.5929","article-title":"Allogeneic T\u00a0cells that express an anti-CD19 chimeric antigen receptor induce remissions of B-cell malignancies that progress after allogeneic hematopoietic stem-cell transplantation without causing graft-versus-host disease","volume":"34","author":"Brudno","year":"2016","journal-title":"J.\u00a0Clin. Oncol"},{"key":"10.1016\/j.ymthe.2017.06.012_bib74","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.2217\/imt.11.131","article-title":"Use of allogeneic NK cells for cancer immunotherapy","volume":"3","author":"Geller","year":"2011","journal-title":"Immunotherapy"},{"key":"10.1016\/j.ymthe.2017.06.012_bib75","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1182\/blood-2008-07-171926","article-title":"Donors with group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia","volume":"113","author":"Cooley","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2017.06.012_bib76","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1182\/blood-2016-03-706317","article-title":"Specific combinations of donor and recipient KIR-HLA genotypes predict for large differences in outcome after cord blood transplantation","volume":"128","author":"Sekine","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2017.06.012_bib77","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.bbmt.2015.09.007","volume":"22","author":"Bao","year":"2016","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.ymthe.2017.06.012_bib78","doi-asserted-by":"crossref","first-page":"2744","DOI":"10.1182\/blood-2014-03-565069","article-title":"KIR B haplotype donors confer a reduced risk for relapse after haploidentical transplantation in children with ALL","volume":"124","author":"Oevermann","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2017.06.012_bib79","doi-asserted-by":"crossref","first-page":"266","DOI":"10.3389\/fimmu.2015.00266","article-title":"Genetic manipulation of NK cells for cancer immunotherapy: techniques and clinical implications","volume":"6","author":"Carlsten","year":"2015","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2017.06.012_bib80","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3389\/fphar.2015.00021","article-title":"Advantages and applications of CAR-expressing natural killer cells","volume":"6","author":"Glienke","year":"2015","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ymthe.2017.06.012_bib81","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/bjh.12282","article-title":"Targeting of acute myeloid leukaemia by cytokine-induced killer cells redirected with a novel CD123-specific chimeric antigen receptor","volume":"161","author":"Tettamanti","year":"2013","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.ymthe.2017.06.012_bib82","doi-asserted-by":"crossref","first-page":"3091","DOI":"10.1182\/blood.V126.23.3091.3091","article-title":"Cord blood derived natural killer cells engineered with a chimeric antigen receptor targeting CD19 and expressing IL-15 have long term persistence and exert potent anti-leukemia activity","volume":"126","author":"Liu","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2017.06.012_bib83","doi-asserted-by":"crossref","first-page":"3255","DOI":"10.1002\/eji.201040568","article-title":"IL-2-activated haploidentical NK cells restore NKG2D-mediated NK-cell cytotoxicity in neuroblastoma patients by scavenging of plasma MICA","volume":"40","author":"Kloess","year":"2010","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.ymthe.2017.06.012_bib84","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1593\/neo.04316","article-title":"Downregulation and\/or release of NKG2D ligands as immune evasion strategy of human neuroblastoma","volume":"6","author":"Raffaghello","year":"2004","journal-title":"Neoplasia"},{"key":"10.1016\/j.ymthe.2017.06.012_bib85","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1097\/CJI.0b013e3181bb46f7","article-title":"IL-2-driven regulation of NK cell receptors with regard to the distribution of CD16+ and CD16- subpopulations and in\u00a0vivo influence after haploidentical NK cell infusion","volume":"33","author":"Huenecke","year":"2010","journal-title":"J.\u00a0Immunother."},{"key":"10.1016\/j.ymthe.2017.06.012_bib86","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1016\/j.jcyt.2013.03.011","article-title":"Cellular therapy of cancer with natural killer cells-where do we stand","volume":"15","author":"Klingemann","year":"2013","journal-title":"Cytotherapy"},{"key":"10.1016\/j.ymthe.2017.06.012_bib87","doi-asserted-by":"crossref","first-page":"4857","DOI":"10.1158\/1078-0432.CCR-08-2810","article-title":"2B4 (CD244) signaling by recombinant antigen-specific chimeric receptors costimulates natural killer cell activation to leukemia and neuroblastoma cells","volume":"15","author":"Altvater","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2017.06.012_bib88","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1182\/blood-2004-12-4797","article-title":"Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells","volume":"106","author":"Imai","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2017.06.012_bib89","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/cgt.2009.61","article-title":"Expression of chimeric antigen receptors in natural killer cells with a regulatory-compliant non-viral method","volume":"17","author":"Li","year":"2010","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.ymthe.2017.06.012_bib90","doi-asserted-by":"crossref","first-page":"830","DOI":"10.3109\/14653249.2012.671519","article-title":"A clinically adaptable method to enhance the cytotoxicity of natural killer cells against B-cell malignancies","volume":"14","author":"Shimasaki","year":"2012","journal-title":"Cytotherapy"},{"key":"10.1016\/j.ymthe.2017.06.012_bib91","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1158\/2326-6066.CIR-14-0114","article-title":"Targeting CD20+ aggressive B-cell non-Hodgkin lymphoma by anti-CD20 CAR mRNA-modified expanded natural killer cells in\u00a0vitro and in NSG mice","volume":"3","author":"Chu","year":"2015","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.ymthe.2017.06.012_bib92","doi-asserted-by":"crossref","first-page":"17481","DOI":"10.1073\/pnas.0804788105","article-title":"Engineering antigen-specific primary human NK cells against HER-2 positive carcinomas","volume":"105","author":"Kruschinski","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2017.06.012_bib93","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1111\/jcmm.12810","article-title":"CD19-CAR engineered NK-92 cells are sufficient to overcome NK cell resistance in B-cell malignancies","volume":"20","author":"Romanski","year":"2016","journal-title":"J.\u00a0Cell. Mol. Med."},{"key":"10.1016\/j.ymthe.2017.06.012_bib94","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.leukres.2008.11.024","article-title":"Transfection with mRNA for CD19 specific chimeric antigen receptor restores NK cell mediated killing of CLL cells","volume":"33","author":"Boissel","year":"2009","journal-title":"Leuk. Res."},{"key":"10.1016\/j.ymthe.2017.06.012_bib95","doi-asserted-by":"crossref","first-page":"e26527","DOI":"10.4161\/onci.26527","article-title":"Retargeting NK-92 cells by means of CD19- and CD20-specific chimeric antigen receptors compares favorably with antibody-dependent cellular cytotoxicity","volume":"2","author":"Boissel","year":"2013","journal-title":"OncoImmunology"},{"key":"10.1016\/j.ymthe.2017.06.012_bib96","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s00262-007-0383-3","article-title":"Expression of a CD20-specific chimeric antigen receptor enhances cytotoxic activity of NK cells and overcomes NK-resistance of lymphoma and leukemia cells","volume":"57","author":"M\u00fcller","year":"2008","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.ymthe.2017.06.012_bib97","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.molonc.2013.12.001","article-title":"Transfection of chimeric anti-CD138 gene enhances natural killer cell activation and killing of multiple myeloma cells","volume":"8","author":"Jiang","year":"2014","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.ymthe.2017.06.012_bib98","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1111\/j.1582-4934.2011.01343.x","article-title":"NK cells engineered to express a GD2 -specific antigen receptor display built-in ADCC-like activity against tumour cells of neuroectodermal origin","volume":"16","author":"Esser","year":"2012","journal-title":"J.\u00a0Cell. Mol. Med."},{"key":"10.1016\/j.ymthe.2017.06.012_bib99","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1182\/blood.V100.4.1265.h81602001265_1265_1273","article-title":"Retargeting of natural killer-cell cytolytic activity to ErbB2-expressing cancer cells results in efficient and selective tumor cell destruction","volume":"100","author":"Uherek","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2017.06.012_bib100","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/mt.2014.219","article-title":"Selective inhibition of tumor growth by clonal NK cells expressing an ErbB2\/HER2-specific chimeric antigen receptor","volume":"23","author":"Sch\u00f6nfeld","year":"2015","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2017.06.012_bib101","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1007\/s00262-012-1212-x","article-title":"Expression of IL-15 in NK cells results in rapid enrichment and selective cytotoxicity of gene-modified effectors that carry a tumor-specific antigen receptor. Cancer Immunol","volume":"61","author":"Sahm","year":"2012","journal-title":"Immunother"},{"key":"10.1016\/j.ymthe.2017.06.012_bib102","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/icb.2013.45","article-title":"Retargeting NK-92 for anti-melanoma activity by a TCR-like single-domain antibody","volume":"91","author":"Zhang","year":"2013","journal-title":"Immunol. Cell Biol."},{"key":"10.1016\/j.ymthe.2017.06.012_bib103","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/S1074-7613(00)80246-0","article-title":"IL-15: a pleiotropic cytokine with diverse receptor\/signaling pathways whose expression is controlled at multiple levels","volume":"4","author":"Tagaya","year":"1996","journal-title":"Immunity"},{"key":"10.1016\/j.ymthe.2017.06.012_bib104","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1056\/NEJMoa1106152","article-title":"Inducible apoptosis as a safety switch for adoptive cell therapy","volume":"365","author":"Di Stasi","year":"2011","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2017.06.012_bib105","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s00109-015-1327-6","article-title":"Efficient generation of gene-modified human natural killer cells via alpharetroviral vectors","volume":"94","author":"Suerth","year":"2016","journal-title":"J.\u00a0Mol. Med. (Berl.)"},{"key":"10.1016\/j.ymthe.2017.06.012_bib106","doi-asserted-by":"crossref","first-page":"195","DOI":"10.3389\/fimmu.2015.00195","article-title":"Utilizing chimeric antigen receptors to direct natural killer cell activity","volume":"6","author":"Hermanson","year":"2015","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2017.06.012_bib107","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1038\/sj.leu.2401769","article-title":"A novel natural killer cell line (KHYG-1) from a patient with aggressive natural killer cell leukemia carrying a p53 point mutation","volume":"14","author":"Yagita","year":"2000","journal-title":"Leukemia"},{"key":"10.1016\/j.ymthe.2017.06.012_bib108","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1080\/14653240802301872","article-title":"Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial","volume":"10","author":"Arai","year":"2008","journal-title":"Cytotherapy"},{"key":"10.1016\/j.ymthe.2017.06.012_bib109","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/leu.2013.279","article-title":"CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in\u00a0vitro and in\u00a0vivo antitumor activity against human multiple myeloma","volume":"28","author":"Chu","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.ymthe.2017.06.012_bib110","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s00262-015-1761-x","article-title":"NK-92: an \u2018off-the-shelf therapeutic\u2019 for adoptive natural killer cell-based cancer immunotherapy. Cancer Immunol","volume":"65","author":"Suck","year":"2016","journal-title":"Immunother"},{"key":"10.1016\/j.ymthe.2017.06.012_bib111","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1182\/blood.V128.22.466.466","article-title":"Intra-tumor injection of CAR-engineered NK cells induces tumor regression and protection against tumor re-challenge","volume":"128","author":"Boissel","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2017.06.012_bib112","doi-asserted-by":"crossref","first-page":"e28147","DOI":"10.4161\/onci.28147","article-title":"Are natural killer cells superior CAR drivers?","volume":"3","author":"Klingemann","year":"2014","journal-title":"OncoImmunology"},{"key":"10.1016\/j.ymthe.2017.06.012_bib113","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.jcyt.2016.10.009","article-title":"Continuously expanding CAR NK-92 cells display selective cytotoxicity against B-cell leukemia and lymphoma","volume":"19","author":"Oelsner","year":"2017","journal-title":"Cytotherapy"},{"key":"10.1016\/j.ymthe.2017.06.012_bib114","doi-asserted-by":"crossref","first-page":"27764","DOI":"10.18632\/oncotarget.8526","article-title":"A combinational therapy of EGFR-CAR NK cells and oncolytic herpes simplex virus 1 for breast cancer brain metastases","volume":"7","author":"Chen","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.ymthe.2017.06.012_bib115","doi-asserted-by":"crossref","first-page":"11483","DOI":"10.1038\/srep11483","article-title":"CAR-engineered NK cells targeting wild-type EGFR and EGFRvIII enhance killing of glioblastoma and patient-derived glioblastoma stem cells","volume":"5","author":"Han","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ymthe.2017.06.012_bib116","doi-asserted-by":"crossref","first-page":"e1119354","DOI":"10.1080\/2162402X.2015.1119354","article-title":"Dual targeting of glioblastoma with chimeric antigen receptor-engineered natural killer cells overcomes heterogeneity of target antigen expression and enhances antitumor activity and survival","volume":"5","author":"Gen\u00dfler","year":"2015","journal-title":"OncoImmunology"},{"key":"10.1016\/j.ymthe.2017.06.012_bib117","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/cgt.2011.66","article-title":"Retargeting 92 cells using an HLA-A2-restricted, EBNA3C-specific chimeric antigen receptor","volume":"19","author":"Tassev","year":"2012","journal-title":"Cancer Gene Ther"},{"key":"10.1016\/j.ymthe.2017.06.012_bib118","doi-asserted-by":"crossref","DOI":"10.1038\/leu.2017.8","article-title":"Preclinical targeting of aggressive T\u00a0cell malignancies using anti-CD5 chimeric antigen receptor","author":"Chen","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.ymthe.2017.06.012_bib119","first-page":"904767","article-title":"Detection of EBV, HBV, HCV, HIV-1, HTLV-I and -II, and SMRV in human and other primate cell lines","volume":"2010","author":"Uphoff","year":"2010","journal-title":"J.\u00a0Biomed. Biotechnol."},{"key":"10.1016\/j.ymthe.2017.06.012_bib120","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1089\/152581601750288975","article-title":"Factors regulating the cytotoxic activity of the human natural killer cell line, NK-92","volume":"10","author":"Maki","year":"2001","journal-title":"J.\u00a0Hematother. Stem Cell Res."},{"key":"10.1016\/j.ymthe.2017.06.012_bib121","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1080\/10428190903026500","article-title":"Variable contribution of monoclonal antibodies to ADCC in patients with chronic lymphocytic leukemia","volume":"50","author":"Weitzman","year":"2009","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.ymthe.2017.06.012_bib122","doi-asserted-by":"crossref","first-page":"86359","DOI":"10.18632\/oncotarget.13411","article-title":"An NK cell line (haNK) expressing high levels of granzyme and engineered to express the high affinity CD16 allele","volume":"7","author":"Jochems","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.ymthe.2017.06.012_bib123","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/978-1-4939-3684-7_20","article-title":"In\u00a0vitro generation of human NK cells expressing chimeric antigen receptor through differentiation of gene-modified hematopoietic stem cells","volume":"1441","author":"Lowe","year":"2016","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.ymthe.2017.06.012_bib124","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1126\/science.285.5428.727","article-title":"Activation of NK cells and T\u00a0cells by NKG2D, a receptor for stress-inducible MICA","volume":"285","author":"Bauer","year":"1999","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2017.06.012_bib125","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1038\/nature03884","article-title":"The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor","volume":"436","author":"Gasser","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2017.06.012_bib126","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1158\/0008-5472.CAN-12-3558","article-title":"A chimeric receptor with NKG2D specificity enhances natural killer cell activation and killing of tumor cells","volume":"73","author":"Chang","year":"2013","journal-title":"Cancer Res."},{"key":"10.1016\/j.ymthe.2017.06.012_bib127","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/imm.12036","article-title":"The immunosuppressive tumour network: myeloid-derived suppressor cells, regulatory T\u00a0cells and natural killer T\u00a0cells","volume":"138","author":"Lindau","year":"2013","journal-title":"Immunology"},{"key":"10.1016\/j.ymthe.2017.06.012_bib128","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1126\/science.285.5428.730","article-title":"An activating immunoreceptor complex formed by NKG2D and DAP10","volume":"285","author":"Wu","year":"1999","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2017.06.012_bib129","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/ni1325","article-title":"NKG2D-mediated signaling requires a DAP10-bound Grb2-Vav1 intermediate and phosphatidylinositol-3-kinase in human natural killer cells","volume":"7","author":"Upshaw","year":"2006","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.ymthe.2017.06.012_bib130","doi-asserted-by":"crossref","first-page":"3201","DOI":"10.4049\/jimmunol.1400330","article-title":"DAP12-based activating chimeric antigen receptor for NK cell tumor immunotherapy","volume":"194","author":"T\u00f6pfer","year":"2015","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.ymthe.2017.06.012_bib131","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1182\/blood.V89.2.610","article-title":"Evidence for the participation of interleukin-2 (IL-2) and IL-4 in the regulation of autonomous growth and tumorigenesis of transformed cells of lymphoid origin","volume":"89","author":"Hassuneh","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2017.06.012_bib132","first-page":"458","article-title":"Mutagenesis by retroviral transgene insertion: risk assessment and potential alternatives","volume":"5","author":"Baum","year":"2003","journal-title":"Curr. Opin. Mol. Ther."},{"key":"10.1016\/j.ymthe.2017.06.012_bib133","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1007\/s11684-011-0159-1","article-title":"Stem cell gene therapy: the risks of insertional mutagenesis and approaches to minimize genotoxicity","volume":"5","author":"Wu","year":"2011","journal-title":"Front. Med."},{"key":"10.1016\/j.ymthe.2017.06.012_bib134","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/nm.2088","article-title":"Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease","volume":"16","author":"Stein","year":"2010","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2017.06.012_bib135","doi-asserted-by":"crossref","first-page":"227ra33","DOI":"10.1126\/scitranslmed.3007280","article-title":"Gene therapy for Wiskott-Aldrich syndrome--long-term efficacy and genotoxicity","volume":"6","author":"Braun","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2017.06.012_bib136","doi-asserted-by":"crossref","first-page":"3132","DOI":"10.1172\/JCI35700","article-title":"Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1","volume":"118","author":"Hacein-Bey-Abina","year":"2008","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.ymthe.2017.06.012_bib137","doi-asserted-by":"crossref","first-page":"9053","DOI":"10.1158\/0008-5472.CAN-10-2880","article-title":"Multiple injections of electroporated autologous T\u00a0cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor","volume":"70","author":"Zhao","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.ymthe.2017.06.012_bib138","doi-asserted-by":"crossref","first-page":"4103","DOI":"10.1182\/blood-2015-02-628354","article-title":"Inducible caspase-9 suicide gene controls adverse effects from alloreplete T\u00a0cells after haploidentical stem cell transplantation","volume":"125","author":"Zhou","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2017.06.012_bib139","doi-asserted-by":"crossref","first-page":"e311","DOI":"10.1038\/emm.2017.42","article-title":"Molecular checkpoints controlling natural killer cell activation and their modulation for cancer immunotherapy","volume":"49","author":"Kwon","year":"2017","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.ymthe.2017.06.012_bib140","doi-asserted-by":"crossref","first-page":"3853","DOI":"10.1158\/0008-5472.CAN-14-3321","article-title":"Multiplex genome-edited T-cell manufacturing platform for \u201coff-the-shelf\u201d adoptive T-cell immunotherapies","volume":"75","author":"Poirot","year":"2015","journal-title":"Cancer Res."},{"key":"10.1016\/j.ymthe.2017.06.012_bib141","doi-asserted-by":"crossref","first-page":"eaaj2013","DOI":"10.1126\/scitranslmed.aaj2013","article-title":"Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T\u00a0cells","volume":"9","author":"Qasim","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2017.06.012_bib142","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1182\/blood.V126.23.2046.2046","article-title":"First clinical application of Talen engineered universal CAR19 T\u00a0cells in B-ALL","volume":"126","author":"Qasim","year":"2015","journal-title":"Blood"}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001617302745?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001617302745?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,8,24]],"date-time":"2023-08-24T06:03:47Z","timestamp":1692857027000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001617302745"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8]]},"references-count":142,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["S1525001617302745"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2017.06.012","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2017,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Engineering Natural Killer Cells for Cancer Immunotherapy","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2017.06.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}]}}